Simple Summary Growth factors are hormone-like molecules able to promote division and
migration of normal cells, but cancer captured the underlying mechanisms to unleash tumor …

Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality
worldwide. Its complexity is influenced by various signal transduction networks that govern …

Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …

Under the selective pressure of therapy, tumours dynamically evolve multiple adaptive
mechanisms that make static interrogation of genomic alterations insufficient to guide …

Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth
factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC) …

Aberrant activation of the epidermal growth factor receptor (EGFR/ERBB1) by erythroblastic
leukemia viral oncogene homolog (ERBB) ligands contributes to various tumor …

During cancer progression and treatment, multiple subclonal populations of tumour cells
compete with one another, with selective pressures leading to the emergence of …

Attempts to develop MET-targeted therapies have historically focused on MET-expressing
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …

Critical driver genomic events in colorectal cancer have been shown to affect the response
to targeted agents that were initially developed under the'one gene, one drug'paradigm of …